CombiChem appoints Peter Myers, formerly of Onyx, Glaxo, as executive vice president of research and chief scientific officer.LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BUSINESS WIRE)--March 13, 1995--CombiChem Inc., a newly established combinatorial chemistry Combinatorial chemistry involves the rapid synthesis or the computer simulation of a large number of different but structurally related molecules. Introduction Synthesis of molecules in a combinatorial fashion can quickly lead to large numbers of molecules. company, Monday announced it has appointed Peter Myers, Ph.D., as executive vice president of research and chief scientific officer. Myers joins CombiChem from Onyx onyx (ŏn`ĭks), variety of cryptocrystalline quartz, differing from agate only in that the bands of which it is composed are parallel and regular. Pharmaceuticals, where he was vice president, drug discovery and development. Myers also served as vice president, chemistry research and director, medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. at Glaxo, following a 16-year career in medicinal chemistry at G.D. Searle & Co. and Reckitt & Colman. "Dr. Myers' understanding of the drug discovery process and his expertise in medical chemistry will benefit CombiChem tremendously," said Robert A. Curtis, president and chief executive officer of CombiChem. "Dr. Myers will guide the development of CombiChem's proprietary technology and spearhead our program of providing products and services to the pharmaceutical and biotechnology industries." Myers will play an important role in establishing research collaborations between CombiChem and pharmaceutical companies to discover and optimize new pharmaceuticals. He will also help CombiChem outlicense small-molecule libraries and transfer combinatorial chemistry capabilities to pharmaceutical and biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. companies. Myers has 26 years' experience as a chemist for pharmaceutical and biotechnology corporations. He has published 60 scientific papers and holds 13 patents. He received both his B.Sc. and Ph.D. from Leads University. CombiChem is a molecular discovery company integrating combinatorial chemistry with computational drug design, bioinformatics Using computers in biological research to analyze or predict the composition of molecules (nucleic acids, proteins, etc.) and model biologic systems. Bioinformatics is most prominent in the Human Genome Project, which has recorded the three billion chemical base pairs that make up the and automated chemical synthesis In chemistry, chemical synthesis is purposeful execution of chemical reactions in order to get a product, or several products. This happens by physical and chemical manipulations usually involving one or more reactions. to identify, optimize and enable broader patent protection for new pharmaceuticals. The company plans to enter research collaborations to discover and optimize new pharmaceuticals; develop and market combinatorial chemistry synthesis equipment; and conduct technology transfer to biotechnology and pharmaceutical companies. CONTACT: CombiChem Inc., La Jolla Robert A. Curtis, 619/453-8090 or Keatinge/Seaton Communications Richard Keatinge, 619/625-2100 or Feinstein Partners Inc. Marcia A. Kean, 617/577-8110 |
|
|||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion